# V930 First in Man (FIM) Study (V930-002)(COMPLETED)

> **NCT00250419** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 26 (actual)

## Conditions studied

- Cancers Expressing HER-2 and/or CEA

## Interventions

- **BIOLOGICAL:** V930

## Key facts

- **NCT ID:** NCT00250419
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2015-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00250419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00250419, "V930 First in Man (FIM) Study (V930-002)(COMPLETED)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00250419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*